Literature DB >> 12868502

Facioscapulohumeral muscular dystrophy (FSHD) myoblasts demonstrate increased susceptibility to oxidative stress.

Sara T Winokur1, Kathy Barrett, Jorge H Martin, James R Forrester, Mariella Simon, Rabi Tawil, Seung-Ah Chung, Peter S Masny, Denise A Figlewicz.   

Abstract

Facioscapulohumeral muscular dystrophy is an autosomal dominant disorder resulting from an unusual genetic mechanism. The mutation, a deletion of 3.3 kb subtelomeric repeats, appears to disrupt the regional regulation of 4q35 g ene expression. The specific gene(s)responsible for facioscapulohumeral muscular dystrophy have not been identified. However, the 'vacuolar/necrotic' phenotype exhibited by facioscapulohumeral muscular dystrophy myoblasts suggests that aberrant gene expression occurs early in facioscapulohumeral muscular dystrophy muscle development. In order to test this hypothesis, global gene expression profiling and in vitro characterization of facioscapulohumeral muscular dystrophy and control myoblasts were carried out. Genes involved in several cellular processes such as oxidative stress were found to be dysregulated. In vitro studies confirmed this susceptibility to oxidative stress, as proliferative stage facioscapulohumeral muscular dystrophy myoblasts exhibit greatly reduced viability when exposed to the oxidative stressor paraquat. This effect was not seen in either normal or disease control myoblasts, or in any of the cell lines upon differentiation to multinucleated myotubes. Immunocytochemical studies of the cyclin dependent kinase inhibitor p21 demonstrated increased expression in facioscapulohumeral muscular dystrophy myoblasts, suggesting an early cell cycle arrest. Another process distinguishing facioscapulohumeral muscular dystrophy from controls involves the transcription of extracellular matrix components. Expression of elastin, decorin, lumican and the extracellular matrix remodeling factor TIMP3 were reduced in facioscapulohumeral muscular dystrophy myoblasts. These studies suggest that facioscapulohumeral muscular dystrophy muscular dystrophy results from a defect in early myogenesis, manifested as increased susceptibility to oxidative stress, morphological aberrations and early cell cycle arrest.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12868502     DOI: 10.1016/s0960-8966(02)00284-5

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  63 in total

1.  The Krüppel-like factor 15 as a molecular link between myogenic factors and a chromosome 4q transcriptional enhancer implicated in facioscapulohumeral dystrophy.

Authors:  Petr Dmitriev; Andrei Petrov; Eugenie Ansseau; Luiza Stankevicins; Sébastien Charron; Elena Kim; Tomas Jan Bos; Thomas Robert; Ahmed Turki; Frédérique Coppée; Alexandra Belayew; Vladimir Lazar; Gilles Carnac; Dalila Laoudj; Marc Lipinski; Yegor S Vassetzky
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

2.  Cytogenetic and immuno-FISH analysis of the 4q subtelomeric region, which is associated with facioscapulohumeral muscular dystrophy.

Authors:  Fan Yang; Chunbo Shao; Vettaikorumakankav Vedanarayanan; Melanie Ehrlich
Journal:  Chromosoma       Date:  2004-05-11       Impact factor: 4.316

3.  A unique library of myogenic cells from facioscapulohumeral muscular dystrophy subjects and unaffected relatives: family, disease and cell function.

Authors:  Sachiko Homma; Jennifer C J Chen; Fedik Rahimov; Mary Lou Beermann; Kendal Hanger; Genila M Bibat; Kathryn R Wagner; Louis M Kunkel; Charles P Emerson; Jeffrey Boone Miller
Journal:  Eur J Hum Genet       Date:  2011-11-23       Impact factor: 4.246

4.  FRG2, an FSHD candidate gene, is transcriptionally upregulated in differentiating primary myoblast cultures of FSHD patients.

Authors:  T Rijkers; G Deidda; S van Koningsbruggen; M van Geel; R J L F Lemmers; J C T van Deutekom; D Figlewicz; J E Hewitt; G W Padberg; R R Frants; S M van der Maarel
Journal:  J Med Genet       Date:  2004-11       Impact factor: 6.318

5.  Wnt/β-catenin signaling suppresses DUX4 expression and prevents apoptosis of FSHD muscle cells.

Authors:  Gregory J Block; Divya Narayanan; Amanda M Amell; Lisa M Petek; Kathryn C Davidson; Thomas D Bird; Rabi Tawil; Randall T Moon; Daniel G Miller
Journal:  Hum Mol Genet       Date:  2013-07-02       Impact factor: 6.150

6.  Defective regulation of microRNA target genes in myoblasts from facioscapulohumeral dystrophy patients.

Authors:  Petr Dmitriev; Luiza Stankevicins; Eugenie Ansseau; Andrei Petrov; Ana Barat; Philippe Dessen; Thomas Robert; Ahmed Turki; Vladimir Lazar; Emmanuel Labourer; Alexandra Belayew; Gilles Carnac; Dalila Laoudj-Chenivesse; Marc Lipinski; Yegor S Vassetzky
Journal:  J Biol Chem       Date:  2013-10-20       Impact factor: 5.157

7.  An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologies.

Authors:  Darko Bosnakovski; Zhaohui Xu; Eun Ji Gang; Cristi L Galindo; Mingju Liu; Tugba Simsek; Harold R Garner; Siamak Agha-Mohammadi; Alexandra Tassin; Frédérique Coppée; Alexandra Belayew; Rita R Perlingeiro; Michael Kyba
Journal:  EMBO J       Date:  2008-10-02       Impact factor: 11.598

8.  DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1.

Authors:  Manjusha Dixit; Eugénie Ansseau; Alexandra Tassin; Sara Winokur; Rongye Shi; Hong Qian; Sébastien Sauvage; Christel Mattéotti; Anne M van Acker; Oberdan Leo; Denise Figlewicz; Marietta Barro; Dalila Laoudj-Chenivesse; Alexandra Belayew; Frédérique Coppée; Yi-Wen Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-05       Impact factor: 11.205

9.  Biphasic myopathic phenotype of mouse DUX, an ORF within conserved FSHD-related repeats.

Authors:  Darko Bosnakovski; Randy S Daughters; Zhaohui Xu; Jonathan M W Slack; Michael Kyba
Journal:  PLoS One       Date:  2009-09-16       Impact factor: 3.240

10.  Myoblasts from affected and non-affected FSHD muscles exhibit morphological differentiation defects.

Authors:  Marietta Barro; Gilles Carnac; Sébastien Flavier; Jacques Mercier; Yegor Vassetzky; Dalila Laoudj-Chenivesse
Journal:  J Cell Mol Med       Date:  2008-05-24       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.